ClinicalTrials.gg
CompletedNCT00641602Updated Mar 26, 2009

A Multicenter, Randomized, Double Blind, Double Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment With Esomeprazole Magnesium (40mg qd) to Lansoprazole (30mg qd) for the Healing of Erosive Esophagitis in Patients With Moderate or Severe Erosive Esophagitis

A Phase 4 interventional study of Esomeprazole and Lansoprazole in Erosive Esophagitis, sponsored by AstraZeneca. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2009-03-26.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,000
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 19 studies testing esomeprazole in Heartburn — none open to participants now, none under way, none of them phase 3. Esomeprazole · Heartburn.

Planned enrollment
2nd of 19
1,000 · median 248
Started
2002
with 2 others
Phase 4
15 of 19
none open now
Registered
11th of 19
by date
Lead sponsor
15 of 19
AstraZeneca

Among the 19 studies testing esomeprazole in Heartburn, this one is the 2nd largest by planned enrollment, is one of 3 that started in 2002, is one of 15 in phase 4, and was the 11th registered.

Heartburn

154 studies on the registry are indexed under Heartburn; 12 are open to participants now.

Browse Heartburn studies →

Open to participants now

None of the 19 studies testing esomeprazole in Heartburn is open now. The open studies under Heartburn, anywhere →

About esomeprazole

Esomeprazole: first FDA approval 2001 (NEXIUM), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 8 Heartburn studies recruiting now, 5 set no upper age limit and 3 stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing esomeprazole in Heartburn as a file.
02

Study summary

This study looks at the healing rates in patients with Erosive Esophagitis (EE) when treated with either esomeprazole or lansoprazole

03

Conditions studied

  • Erosive Esophagitis

Browse trials for

Keywords

  • Erosive Esophagitis
  • Nexium
  • Heartburn
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Episodes of heartburn (described as a burning feeling, rising from the stomach or lower part of the chest up towards the neck) for 2 days or more during the last 7 days prior to baseline.
  • Confirmed Erosive Esophagitis within 1 week prior to starting the study.

Exclusion criteria

Exclusion Criteria:

  • Any signs of gastrointestinal bleeding at the time of the starting the study.
  • Any previous gastric or esophageal surgery.
  • Various gastrointestinal diseases as listed in the protocol.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
1,000 participants (estimated)

Study arms

  • Experimental
    1

    Nexium

    Drug: Esomeprazole

  • Active comparator
    2

    Prevacid

    Drug: Lansoprazole

Interventions

06

What researchers measure

Primary outcomes

  1. To compare the difference in healing rates of erosive esophagitis (EE) between esomeprazole 40 mg qd (E40) and lansoprazole 30 mg qd (L30) in patients with moderate or severe EE, defined as Grade C or D in the Los Angeles (LA) Classification scale.

    Time frame: Esophagogastroduodenoscopy (EGD) at baseline and then week 4 and week 8 (if not healed at week 4)

Secondary outcomes

  1. 1. To compare the difference in the resolution of, and relief of, the investigator evaluated GERD symptoms of heartburn, acid regurgitation, dysphagia, and epigastric pain between E40 and L30 at week 4 of treatment in patients with moderate or severe EE.

    Time frame: Esophagogastroduodenoscopy (EGD) at baseline and then week 4 and week 8 (if not healed at week 4)

  2. 1. To compare the difference between E40 and L30 in the occurrence of heartburn symptoms as reported in the patient's daily diary.

    Time frame: Dairy card to be completed by patient daily

  3. To evaluate safety and tolerability of E40 compared to that of L30 in patients with moderate or severe EE.

    Time frame: Adverse event collection on an ongoing basis

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2002, a primary completion of Aug 2003 and a completion of Aug 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2008
First posted
Mar 24, 2008
Start
Dec 2002
Primary completionActual
Aug 2003
CompletionActual
Aug 2003
Last update
Mar 26, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00641602
Lead sponsor
AstraZeneca
First posted
Mar 24, 2008
Start date
Dec 2002
Primary completion
Aug 2003
Completion
Aug 2003
Last update
Mar 26, 2009

Study contacts

Paula Fernstrom
study director · Nexium Global Product Director, AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esomeprazole

Start the discussion